Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Bart De Goeij"'
Autor:
Michelle Kinder, Nizar J. Bahlis, Fabio Malavasi, Bart de Goeij, Alexander Babich, Jocelyn Sendecki, Joshua Rusbuldt, Kevin Bellew, Colleen Kane, Niels W.C.J. van de Donk
Publikováno v:
Haematologica, Vol 106, Iss 7 (2021)
Externí odkaz:
https://doaj.org/article/04bb5056edc14521a6d3677dd42ad9b6
Autor:
Kate Sasser, Kristel Kemper, Ellis Gielen, Mischa Houtkamp, Peter Boross, Stefanie De Poot, Patrick Engelberts, Bart de Goeij, David Satijn
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/cba5dcfc8a634b10bc5ba77b06d69ba0
Autor:
Nizar J. Bahlis, Michelle Kinder, Fabio Malavasi, Jocelyn Sendecki, Bart De Goeij, Kevin Bellew, Niels W.C.J. van de Donk, Alexander Babich, Joshua J. Rusbuldt, Colleen Kane
Publikováno v:
Haematologica. 106:2004-2008
Autor:
Ellis Gielen, Stefanie De Poot, David Satijn, Bart De Goeij, Kristel Kemper, Esther C.W. Breij, Peter Boross, Saskia M. Burm, Kate Sasser, Mischa Houtkamp, Patrick J. Engelberts
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background The tumor-associated antigen 5T4 is expressed across a wide range of solid cancers. DuoBody-CD3x5T4 is a bispecific antibody (bsAb) that crosslinks CD3 on T cells with 5T4 on tumor cells, thereby inducing T-cell activation and T-cell media
Autor:
Grietje Andringa, Andreas Lingnau, Laurens P. Kil, Niels W.C.J. van de Donk, David Satijn, Tuna Mutis, A. Kate Sasser, Kristine A. Frerichs, Andreas Freidig, Tahamtan Ahmadi, Bart De Goeij, Berris van Kessel, Esther C.W. Breij, Maarten L. Janmaat
Publikováno v:
De Goeij, B E C G, Janmaat, M L, Andringa, G, Kil, L, Van Kessel, B, Frerichs, K A, Lingnau, A, Freidig, A, Mutis, T, Sasser, A K, Breij, E C W, Van de Donk, N W C J, Ahmadi, T & Satijn, D 2019, ' Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies ', Blood, vol. 134 . https://doi.org/10.1182/blood-2019-125788
Blood, 134. American Society of Hematology
Blood, 134. American Society of Hematology
HexaBody-CD38 (GEN3014) is a novel, hexamerization-enhanced human IgG1 targeting CD38 with superior complement dependent cytotoxicity (CDC) activity, in addition to other effector mechanisms. HexaBody-CD38 carries the E430G mutation and binds a diffe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7dc52409d185e513ba4070482b7ad83c
https://research.vumc.nl/en/publications/5eca2ce7-5698-4119-8c31-e64e1ace7b9d
https://research.vumc.nl/en/publications/5eca2ce7-5698-4119-8c31-e64e1ace7b9d
Autor:
Jeroen van den Brakel, Ida H. Hiemstra, David Satijn, Sanne van Dooremalen, Maarten L. Janmaat, Esther C.W. Breij, Peter Boross, Tahamtan Ahmadi, Bart De Goeij, Laurens P. Kil, Sieto Bosgra, Grietje Andringa, Wessel ten Hagen, A. Kate Sasser
Publikováno v:
Blood. 136:19-20
HexaBody®-CD38 (GEN3014) is a next-generation CD38-specific IgG1 molecule with a hexamerization-enhancing mutation that leads to highly efficient induction of complement-dependent cytotoxicity (CDC) upon binding to CD38 positive tumor cells. HexaBod
Autor:
Simone de Haij, Kristin Strumane, Wim K. Bleeker, Edward Van Den Brink, Matthias Peipp, Bart De Goeij, Tom Vink, Christian Kellner, Rob N. de Jong, Thilo Riedl, Paul W. H. I. Parren
Publikováno v:
mAbs. 6:392-402
The human epidermal growth factor receptor (HER)2 provides an excellent target for selective delivery of cytotoxic drugs to tumor cells by antibody-drug conjugates (ADC) as has been clinically validated by ado-trastuzumab emtansine (Kadcyla(TM)). Whi
Autor:
Christopher Chiu, Bart De Goeij, Jeroen J. Lammerts van Bueren, Michelle Kinder, Stephen I. Rudnick, Amy Axel, Amy Wong, Alex Babich, Colleen Kane, Jocelyn Sendecki, Mi Ta, Kevin Bellew, Mark Mendonca
Publikováno v:
Cancer Research. 79:2970-2970
Background: The outcome of multiple myeloma (MM) patients has been dramatically improved by the monoclonal antibody (mAb) daratumumab (DARA). DARA is a human IgG1κ mAb specific for CD38 and approved for the treatment of newly diagnosed and relapsed/
Autor:
John M. Lambert, Bart De Goeij
Publikováno v:
Current opinion in immunology. 40
The clinical success of Adcetris(®) (brentuximab vedotin) and Kadcyla(®) (ado-trastuzumab emtansine) has sparked clinical development of novel ADCs. These powerful anti-cancer agents are designed to allow specific targeting of highly potent cytotox
Autor:
Marinus H. J. van Oers, René Spijker, Bart De Goeij, Arnon P. Kater, Laura A. Smit, Carel J. M. van Noesel, Delfine Y.H. Hallaert, Annelieke Jaspers, Eric Eldering
Publikováno v:
Blood, 109(4), 1660-1668. American Society of Hematology
The gradual accumulation of chronic lymphocytic leukemia (B-CLL) cells is presumed to derive from proliferation centers in lymph nodes and bone marrow. To what extent these cells possess the purported antiapoptotic phenotype of peripheral B-CLL cells